Eli Lilly and Company(LLY) - Stock detail

Eli Lilly and Company

US
LLY
Eli Lilly and Company(Listing date: 07/09/1970)

Eli Lilly and Company was incorporated in Indiana in 1901, with its predecessor being a pharmaceutical manufacturing enterprise founded by Colonel Eli Lilly in Indianapolis, Indiana in 1876. The company develops, manufactures and markets important pharmaceutical products. Its mission is to combine "Caring" and "Discovery" to create better lives for people around the world.

AI Debate JudgeBuy
Generated at:2026-03-05 05:41:52
Data source: real-time quotes, news and fundamental analysis, analysis date: 2026-03-04
  • Exceptional fundamental performance justifies the premium valuation with trailing P/E of 47.85
  • Furthermore, 94.9% net income growth and 44.7% revenue growth demonstrate strong underlying performance
  • Moreover, margin expansion to 31.67% shows operational efficiency beyond just top-line growth
  • Additionally, recent FDA actions against compounded GLP-1 drugs strengthen Lilly's competitive position
  • Most importantly, pipeline diversification into immunology, oral GLP-1s, and Alzheimer's provides multiple growth drivers
  • Technically, the stock is oversold after a 9.4% pullback representing healthy consolidation within a longer-term uptrend
Bear Case
  • Forward P/E of 91.43 indicates valuation concerns
  • Current price assumes perfection and is vulnerable to multiple contraction
  • Competitive threats from Novo Nordisk pose significant risk
  • Potential growth deceleration after initial launch cycle
  • Technical weakness suggests underlying problems
Bull Case
  • Trailing P/E of 47.85 based on actual earnings is reasonable
  • Exceptional 94.9% YoY net income growth demonstrates strength
  • Margin expansion to 31.67% shows operational efficiency
  • $100+ billion obesity market has room for multiple winners
  • Pipeline diversification provides multiple growth drivers
  • Technical pullback represents oversold consolidation rather than breakdown

Price Targets

Analysis Summary

1-Month Target (Conservative): $1,060-$1,070

  • Based on technical rebound to previous resistance levels
  • Supported by positive news flow from regulatory approvals
  • Represents 6-7% upside from current levels

3-Month Target (Baseline): $1,150-$1,250

  • Based on fundamental valuation using trailing P/E of 47.85 and projected EPS growth
  • Aligns with Q1 2026 earnings expectations showing continued GLP-1 sales growth
  • Represents 15-25% upside from current levels

6-Month Target (Optimistic): $1,350-$1,450

  • Assuming continued market expansion and successful pipeline execution
  • Oral GLP-1 progress and additional regulatory approvals
  • Represents 35-45% upside potential

Action Strategy

Strategy Summary
  1. Entry Strategy: Accumulate positions near current levels ($1003-$1010) with additional buying on any dips to $980-$990
  1. Position Sizing: 3-5% portfolio allocation given the stock’s historical volatility
  2. Stop-Loss: $950 (5.3% below current price, respecting historical maximum adverse excursion patterns)
  3. Profit-Taking: Scale out of positions at target levels to manage risk given low historical target achievement rate
AI Bull vs AI Bear
Round-by-round arguments

Round 1 - Bear case

  • Stock trades at a high dynamic P/E of 91.43, pricing in perfection and vulnerable to a violent contraction. Technicals confirm a downtrend, with price below all major moving averages and a negative MACD. Competition from Novo Nordisk is intensifying, and the market will see more entrants, eroding pricing power. The CEO's skepticism on AI in R&D highlights a potential long-term risk to its moat. The current price is a valuation trap.

Detail Preview

Excellent. Let's begin. I've reviewed the bullish case for Eli Lilly, and while it's compelling on the surface, it's built on a foundation of extreme optimism and ignores significant, mounting risks. The current price of $1,003.57 isn't a dip to buy; it's a gravity-defying act that's beginning to falter. Let me address the bullish points directly. First, on valuation: "High but justified by growth." This is the most…

Round 2 - Bear case

  • Eli Lilly's P/E of 91.43 prices in a flawless, competition-free future, making it vulnerable to a multiple contraction. The exceptional 94.9% net income growth is a peak launch-cycle event that will decelerate. Competition is a major threat from Novo Nordisk and others developing next-generation drugs, which will erode pricing power. Technically, the stock is in a confirmed downtrend, trading below all major moving averages with over 92% of positions underwater.

Detail Preview

Right, let's cut through the bullish narrative. I've seen this story before – a stock runs up on hype, gets priced for perfection, and then reality sets in. With Eli Lilly trading at over a thousand dollars a share, the downside risk is absolutely massive. The bullish argument is built on a house of cards, and I'm here to point out the cracks. My esteemed bullish colleague points to a P/E of 47.85 and calls it "justi…

Round 1 - Bull case

  • The high P/E ratio of 47.85 is justified by exceptional 94.9% YoY net income growth and 44.7% revenue growth. The $100+ billion GLP-1 market is underpenetrated, allowing multiple winners, and FDA action against compounded drugs strengthens Lilly's position. The CEO's AI skepticism reflects a focus on core pharmaceutical strengths. Technical indicators like RSI and Bollinger Bands suggest the stock is oversold and consolidating, not breaking down, after a major run.

Detail Preview

Alright, let's cut through the noise. I’ve reviewed the bearish argument, and while it raises some classic concerns, it fundamentally misses the forest for the trees. The bear case is a snapshot of a temporary pullback, completely ignoring the seismic, long-term growth story unfolding here. Let's engage directly with those points. Refuting the Bearish Arguments & Addressing Concerns You call the dynamic P/E of 91.43…

Round 2 - Bull case

  • Trailing P/E is 47.85 based on realized earnings, not the dynamic P/E, and this multiple is contracting. Growth is a launchpad, not a peak, with margin expansion to 31.67% showing operational leverage. The obesity market is a $100+ billion land grab, not zero-sum, and FDA actions protect branded leaders. The pipeline is diversifying into immunology, oral GLP-1s, and Alzheimer's. The 9.4% pullback is a healthy consolidation with oversold technicals, not a breakdown.

Detail Preview

Excellent points to address. Let's separate the short-term noise from the long-term trajectory. While my colleague focuses on a temporary technical pullback and theoretical peak growth, I see a company hitting its absolute strategic stride with multiple growth vectors just beginning to unfold. Let's start with the core of your argument: the "peak" growth and valuation. You're right, a dynamic P/E of 91.43 looks astro…

Round 1 - Bear case

  • Stock trades at a high dynamic P/E of 91.43, pricing in perfection and vulnerable to a violent contraction. Technicals confirm a downtrend, with price below all major moving averages and a negative MACD. Competition from Novo Nordisk is intensifying, and the market will see more entrants, eroding pricing power. The CEO's skepticism on AI in R&D highlights a potential long-term risk to its moat. The current price is a valuation trap.

Detail Preview

Excellent. Let's begin. I've reviewed the bullish case for Eli Lilly, and while it's compelling on the surface, it's built on a foundation of extreme optimism and ignores significant, mounting risks. The current price of $1,003.57 isn't a dip to buy; it's a gravity-defying act that's beginning to falter. Let me address the bullish points directly. First, on valuation: "High but justified by growth." This is the most…

Round 1 - Bull case

  • The high P/E ratio of 47.85 is justified by exceptional 94.9% YoY net income growth and 44.7% revenue growth. The $100+ billion GLP-1 market is underpenetrated, allowing multiple winners, and FDA action against compounded drugs strengthens Lilly's position. The CEO's AI skepticism reflects a focus on core pharmaceutical strengths. Technical indicators like RSI and Bollinger Bands suggest the stock is oversold and consolidating, not breaking down, after a major run.

Detail Preview

Alright, let's cut through the noise. I’ve reviewed the bearish argument, and while it raises some classic concerns, it fundamentally misses the forest for the trees. The bear case is a snapshot of a temporary pullback, completely ignoring the seismic, long-term growth story unfolding here. Let's engage directly with those points. Refuting the Bearish Arguments & Addressing Concerns You call the dynamic P/E of 91.43…

Round 2 - Bear case

  • Eli Lilly's P/E of 91.43 prices in a flawless, competition-free future, making it vulnerable to a multiple contraction. The exceptional 94.9% net income growth is a peak launch-cycle event that will decelerate. Competition is a major threat from Novo Nordisk and others developing next-generation drugs, which will erode pricing power. Technically, the stock is in a confirmed downtrend, trading below all major moving averages with over 92% of positions underwater.

Detail Preview

Right, let's cut through the bullish narrative. I've seen this story before – a stock runs up on hype, gets priced for perfection, and then reality sets in. With Eli Lilly trading at over a thousand dollars a share, the downside risk is absolutely massive. The bullish argument is built on a house of cards, and I'm here to point out the cracks. My esteemed bullish colleague points to a P/E of 47.85 and calls it "justi…

Round 2 - Bull case

  • Trailing P/E is 47.85 based on realized earnings, not the dynamic P/E, and this multiple is contracting. Growth is a launchpad, not a peak, with margin expansion to 31.67% showing operational leverage. The obesity market is a $100+ billion land grab, not zero-sum, and FDA actions protect branded leaders. The pipeline is diversifying into immunology, oral GLP-1s, and Alzheimer's. The 9.4% pullback is a healthy consolidation with oversold technicals, not a breakdown.

Detail Preview

Excellent points to address. Let's separate the short-term noise from the long-term trajectory. While my colleague focuses on a temporary technical pullback and theoretical peak growth, I see a company hitting its absolute strategic stride with multiple growth vectors just beginning to unfold. Let's start with the core of your argument: the "peak" growth and valuation. You're right, a dynamic P/E of 91.43 looks astro…

End of debate